^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
Excerpt:
...- For Cohort 1 and Cohort 1a: HER2-overexpression (IHC 2+ or 3+) status must be assessed and confirmed by Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or equivalent, from an archival tumor tissue sample...
Trial ID:
Source:
Title:
975P - Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
Published date:
09/05/2022
Excerpt:
We report the results of T-DXd in pts with HER2-OE NSCLC….Both T-DXd doses had encouraging and consistent antitumor activity in heavily pretreated pts with HER2-OE NSCLC.
Trial ID:
Source:
Title:
Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
Published date:
01/29/2021
Excerpt:
In the interim analysis of cohort 1 from the DESTINY-Lung01 phase 2 trial...patients with HER2 overexpressing (defined as IHC3+ or IHC2+) metastatic NSCLC treated with ENHERTU (6.4 mg/kg) (n=49)...One complete response and 11 partial responses were observed. Patients achieved a DCR of 69.4% (34/49 patients [CI 95%, range, 54.6-81.8 patients]) with a median PFS of 5.4 months (95% CI, range, 2.8-7.0 months).
Trial ID:
